

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours ID1001

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> Fennec Pharmaceuticals (Sodium thiosulfate) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> Auditory Verbal UK Beacon Black Health Agency for Equality British Deaf Association Cancer Black Care Cancer Equality Catholic Deaf Association Childhood Cancer Parents Alliance Children with Cancer Christian Deaf Link UK Cochlear Implanted Children's Support Group Deafblind UK deafPLUS DELTA Hearing LINK Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie Meniere's Society National Association of Deafened People National Cochlear Implant Users Association National Deaf Children's Society Royal Association for Deaf People 	<p><u>General</u></p> <ul style="list-style-type: none"> All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> None <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> Action on Hearing Loss Cochrane UK Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> Public Health Wales

Provisional stakeholder list for the evaluation of anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours ID1001

Issue date: February 2024

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal National Institute for Deaf People • Sense • South Asian Health Foundation • Specialised Healthcare Alliance • Teenage Cancer Trust • Tenovus Cancer Care • Young Lives vs Cancer • UK Council on Deafness <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • British Academy of Audiology • British Association of Audiological Physicians • British Association of Educational Audiologists • British Association of Otolaryngologists, Head & Neck Surgeons • British Association of Paediatricians in Audiology • British Association of Teachers of the Deaf • British Cochlear Implant Group • British Oncology Pharmacy Association • British Psychosocial Oncology Society • British Society of Audiology • British Society of Hearing Aid Audiologists • Cancer Research UK • Chartered Society of Physiotherapy • Children’s Cancer & Leukaemia Group • Neonatal and Paediatric Pharmacists Group • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics & Child Health • Royal College of Pathologists • Royal College of Physicians 	<ul style="list-style-type: none"> • UK Health Security Agency

Provisional stakeholder list for the evaluation of anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours ID1001

Issue date: February 2024

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Speech and Language Therapists • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association • UK Oncology Nursing Society • Vestibular Interdisciplinary Working Group (VIWG) <p><u>Others</u></p> <ul style="list-style-type: none"> • Great Ormond Street Hospital (London) • Department of Health and Social Care • Health Technology Wales (HTW) • NHS England 	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These

Provisional stakeholder list for the evaluation of anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours ID1001

Issue date: February 2024

organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.